Entecavir VA Page_ipad size

Treatment of chronic hepatitis B could require life-long therapy.1

Introducing Trusted with long term clinical trial data of 10 years1 Prolong Efficacy Prolonged Prolong Safety rotection

Prolong Efficacy 10 year long Entecavir (ETV) therapy was associated with a low rate of liver-related HBV disease progression, comparable with other standard-of-care HBV.1 Patients with events (%)Figure: Liver-related HBV disease progression Virologic response was con rmed and maintained in 79.7% and 7 60.8% of patients in the ETV and 6 non-ETV groups.1 5 Prolonged rotection 4 3 2 1 ETV events/N = 350/6216 Non-ETV event/N = 375/6162 0 BL 12 24 36 48 60 72 84 96 108 120 Months

Prolong Safety ETV was associated with a low rate of treatment-related severe adverse events, consistent with the known ETV safety pro le.1 Patients with events (%) Figure: Proportion of patients who ETV provided a high margin of experienced HCC safety and was not associated with a higher occurrence of 7 hepato-cellular carcinoma (HCC) 6 or Non-HCC malignancies. 1 5 Prolonged rotection 4 3 2 1 ETV events/N = 240/6216 Non-ETV event/N = 263/6162 0 BL 12 24 36 48 60 72 84 96 108 120 Months Reference: 1. Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, et al., Outcomes of Long-term Treatment of Chronic HBV Infection with Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clin Gastroenterol Hepatol. 2020;18(2):457-467.e21.

For achieving Prolong Protection For the use of a Registered Medical Prac oner or Hospital or Laboratory only. Expiry date: April 2022 Prescribing informa on of the products available on request. All the claims are based on authen c data, available on request. Images are for representa on purpose only. Not of an actual Pa ent. Note: This detailer is meant only for communica on with the Registered Medical Prac oners. Copying, circula on or reproduc on of the same is strictly prohibited. Any unauthorized person having possession of this document should discard the same or inform/ no fy/ return to Cipla Ltd., Registered Medical Prac oner shall use their discre on to prescribe the drug/s of their choice. Disclaimer: The concept in this publica on is designed and developed by ScienArt Medical Communica ons for Cipla Ltd. and is only for informa onal purposes. The ma er published herein has been developed by the clinicians and medical writers. Although great care has been taken in compiling and checking the informa on, the authors, ScienArt Medical Communica ons and its associates or agents, and sponsors or Cipla shall not be responsible, or in any way liable for any errors, omission or inaccuracies in this publica on whether arising from negligence or otherwise however, or for any consequences arising therefrom. The inclusion or exclusion of any product does not mean that the publisher or author advocates or rejects its use either generally or in any par cular field or fields. Any advice regarding the management of the medical condi on is totally in the discre on of the doctor/ Medical Specialist. No part of this may be reproduced, transmi ed or stored in any form or by any means either mechanically or electronically. Copying and circula on of this document is strictly prohibited.